These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 24603276)
1. Myeloproliferative hypereosinophilic syndrome presenting as cardiac failure and response to imatinib. Desai N; Morkhandikar S; Sahay R; Jijina F; Patil P Am J Ther; 2014; 21(2):e35-7. PubMed ID: 24603276 [TBL] [Abstract][Full Text] [Related]
2. [Disorders with eosinophilia, treatment of hypereosinophilic syndrome]. Borbényi Z Orv Hetil; 2005 May; 146(18 Suppl 1):911-6. PubMed ID: 15921304 [TBL] [Abstract][Full Text] [Related]
3. [Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome]. Menif S; Ben Romdhane N; Hafsia R Rev Med Interne; 2008 Jan; 29(1):65-7. PubMed ID: 18036706 [TBL] [Abstract][Full Text] [Related]
4. Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants. Roufosse F; Goldman M; Cogan E Semin Respir Crit Care Med; 2006 Apr; 27(2):158-70. PubMed ID: 16612767 [TBL] [Abstract][Full Text] [Related]
5. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. Pardanani A; Tefferi A Leuk Res; 2004 May; 28 Suppl 1():S47-52. PubMed ID: 15036941 [TBL] [Abstract][Full Text] [Related]
6. The results of imatinib therapy for patients with primary eosinophilic disorders. Helbig G; Stella-Holowiecka B; Grosicki S; Bober G; Krawczyk M; Wojnar J; Reiter A; Hochhaus A; Holowiecki J Eur J Haematol; 2006 Jun; 76(6):535-6. PubMed ID: 16608506 [No Abstract] [Full Text] [Related]
7. A case of myeloid neoplasm associated with eosinophilia and KIAA1509-PDGFRβ responsive to combination treatment with imatinib mesylate and prednisolone. Wang JR; Yen CC; Gau JP; Hsiao LT; Liu CY; Pai JT; Tzeng CH; Teng HW J Clin Pharm Ther; 2010 Dec; 35(6):733-6. PubMed ID: 21054467 [TBL] [Abstract][Full Text] [Related]
8. [Sustained hematologic response in chronic eosinophilic leukemia with low dose imatinib. Report of one case]. Torres C D; Chandía M Rev Med Chil; 2014 Apr; 142(4):516-20. PubMed ID: 25117044 [TBL] [Abstract][Full Text] [Related]
9. [Efficiency of imatinib in polyserositis revealing a FIP1L1-PDGFRA-negative hypereosinophilic syndrome]. Green L; Kahn JE; Dufour JF; Le Scanff J; Charhon A; Broussolle C; Sève P Rev Med Interne; 2010 Apr; 31(4):305-8. PubMed ID: 20167399 [TBL] [Abstract][Full Text] [Related]
10. [A man with oral ulcers caused by hypereosinophilic syndrome and a good response to the tyrosine-kinase inhibitor imatinib]. Verstappen MC; Mattijssen V; van der Reijden BA; van der Heijden AJ; Wahab PJ; de Vries RA Ned Tijdschr Geneeskd; 2006 May; 150(21):1188-92. PubMed ID: 16768284 [TBL] [Abstract][Full Text] [Related]
11. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. Cools J; DeAngelo DJ; Gotlib J; Stover EH; Legare RD; Cortes J; Kutok J; Clark J; Galinsky I; Griffin JD; Cross NC; Tefferi A; Malone J; Alam R; Schrier SL; Schmid J; Rose M; Vandenberghe P; Verhoef G; Boogaerts M; Wlodarska I; Kantarjian H; Marynen P; Coutre SE; Stone R; Gilliland DG N Engl J Med; 2003 Mar; 348(13):1201-14. PubMed ID: 12660384 [TBL] [Abstract][Full Text] [Related]
12. A case of hypereosinophilic syndrome presenting with chronic cough successfully treated with imatinib. Kobayashi M; Kubota T; Uemura Y; Taguchi H Respirology; 2009 Mar; 14(2):302-4. PubMed ID: 19192229 [TBL] [Abstract][Full Text] [Related]
13. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Coutré S; Gotlib J Semin Cancer Biol; 2004 Feb; 14(1):23-31. PubMed ID: 14757533 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic and therapeutic management in patients with hypereosinophilic syndromes. Helbig G; Kyrcz-Krzemień S Pol Arch Med Wewn; 2011; 121(1-2):44-52. PubMed ID: 21346698 [TBL] [Abstract][Full Text] [Related]
15. [Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition]. Moles MP; Landry J; Roche-Lestienne C; Godon A; Schmidt-Tanguy A; Gardembas M; Le Clech C; Verret JL; Zandecki M; Blanchet O Ann Biol Clin (Paris); 2005; 63(3):317-22. PubMed ID: 15951264 [TBL] [Abstract][Full Text] [Related]
16. Successful treatment of myeloid neoplasms associated with PDGFRA rearrangement with imatinib mesylate. Sun CY; Hu Y; Chu ZB; Guo T; He J Int J Hematol; 2009 Jan; 89(1):66-70. PubMed ID: 19096755 [TBL] [Abstract][Full Text] [Related]
17. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Coutré S; Gotlib J Semin Cancer Biol; 2004 Aug; 14(4):307-15. PubMed ID: 15305431 [TBL] [Abstract][Full Text] [Related]
18. Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib. Hofmann SC; Technau K; Müller AM; Lübbert M; Bruckner-Tuderman L J Am Acad Dermatol; 2007 May; 56(5 Suppl):S68-72. PubMed ID: 17097375 [TBL] [Abstract][Full Text] [Related]
19. Hypereosinophilic syndrome: two case reports of contrasting variants. Szymanski J; Rappaport E South Med J; 2005 Apr; 98(4):467-8. PubMed ID: 15898525 [TBL] [Abstract][Full Text] [Related]